Outpatient patterns of care and longitudinal intensity of antiretroviral therapy for HIV-infected drug users

Medical Care

Volumn 40, Issue 10, 2002, Pages 976-995

  Laine, Christine ^a   Hauck, Walter W ^a   Turner, Barbara J ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antiretroviral therapy; Drug abuse; HIV infection; Medicaid; Medical care

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADDICTION; ADULT; AMBULATORY CARE; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; CONFIDENCE INTERVAL; DRUG COMBINATION; DRUG USE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEDICAID; METHODOLOGY; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

ADULT; AMBULATORY CARE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; CONFIDENCE INTERVALS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION REVIEW; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICAID; MIDDLE AGED; NEW YORK; PHYSICIAN'S PRACTICE PATTERNS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SUBSTANCE-RELATED DISORDERS;

EID: 0036780917     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-200210000-00014     Document Type: Article

References (40)

1. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-454.
2. Cunningham WE, Markson E, Andersen RM, et al. Prevalence and predictors of highly active antiretroviral therapy use in persons with HIV infection in the US. J Acquir Immun Defic Syndr 2000;25:115-123.
3. Carried MP, Moatti JP, Vlahov D, el al. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group. J Epidemiol Comm Health 1999;53:4-8.
4. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998;280:547-549.
5. Stone VE, Mansourati FF, Poses RM, et al. Relation of physician specialty and HIV/AIDS experiences to choice of guideline recommended antiretroviral therapy. J Gen Intern Med 2002(in press).
6. Bassetti S, Battegay M, Furrer H, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study J Acquir Immune Defic Syndr 1999;21:114-119.
7. Edlin BR, Erringer EA, Lorvick J, et al. Receipt of protease inhibitor therapy by street-recruited drug users in San Francisco, California. Int Conf AIDS. Geneva 1998;12:835 (abstract no. 42309).
8. Andersen R. Early access to HAART affected by gender, race, age and education level. Health Serv Res 2000;2:389-416
9. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-1539.
10. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-733.
11. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. JAMA 1997;277:1962-1969.
12. Keyes M, Andrews R, et al. A methodology for building an AIDS research file using Medicaid claims and administrative databases. J Acquir Immune Defic Syndr 1991;4:1015-1024.
13. Fanning TR, Turner BJ, Cosier LE, et al. Quality of Medicaid data for HIV/AIDS: examination of a statewide database. AIDS Pub Pol J 1995;10:39-47.
14. Turner BJ, McKee L, Silverman NS, et al. Prenatal care and birth outcomes of a cohort of HV-infected women. J Acquir Immune Defic Syndr 1996;12:259-267.
15. Laine C, Hauck WW, Gourevitch MN, et al. Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs. JAMA 2001;285:2355-2362.
16. Turner BJ, McKee L, Fanning T, et al. AIDS specialist versus generalist ambulatory care for advanced HIV infection and impact on hospital use. Med Care 1994;32:902-916.
17. Anonymous. Designated care programs for patients with AIDS and HIV-related illnesses in designated care centers. New York State J Med 1989;89:542-543.
18. Turner BJ, Cunningham WE, Duan N, et al. Delayed medical care after diagnosis in a US national probability sample of HIV-infected persons. Arch Intern Med 2000;160:2614-2622.
19. Anonymous. State of New York Department of Health Memorandum. Health Facilities Series: H-23, D&TC-17, HMO-16, 1993;93-96.
20. Lipsitz SR, Kyungmann K, Zhao L. Analysis of repeated categorical data using generalized estimating equations. Stat Med 1994;13:1149-1163.
21. D'Agostino RB. Tutorial in biostatistics propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-2281.
22. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4+ lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
23. Anonymous. Drugs for AIDS and associated infections. Med Letter 1995;37:87-94.
24. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA 1996;276:146-154.
25. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. JAMA 1997;277:1962-1969.
26. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998;280:78-86.
27. Markson LE, Cosler LE, Turner BJ. Implications of generalists' slow adoption of zidovudine in clinical practice. Arch Intern Med 1994;154:1497-1504.
28. Turner BJ, Zhang D, Laine CL, et al. Association of provider and patient characteristics with HIV-infected women's antiretroviral therapy regimen. J Acquir Immune Defic Syndr 2001;27:20-29.
29. Kitahata MM, Koepsell TD, Deyo RA, et al. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med 1996;334:701-706.
30. Laine C, Markson LE, McKee LJ, et al. The relationship of clinic experience with advanced HIV and survival of women with AIDS. AIDS 1998;12:417-424.
31. Hecht FM, Wilson IB, Wu AW, et al. Optimizing care for persons with HIV infection. Ann Intern Med 1999;131:136-143.
32. Zuger A, Sharp VL. HIV specialists: the time has come. JAMA 1997;278:1131-1132.
33. Lewis CE. Management of patients with HIV/AIDS. Who should care? JAMA 1997;278:1133-1135.
34. Turner BJ, Newschaffer CJ, Zhang D, et al. Translating clinical trial results into practice: the effect of an AIDS clinical trial on prescribed antiretroviral therapy for HIV-infected, pregnant women. Ann Intern Med 1999;130:979-986.
35. Mannheimer S, El-Sadr W, Flowers J, et al. Virologie response to antiretroviral therapy among HIV-infected injection drug users. Int Conf AIDS Geneva 1998;12:603 (abstract no 499/32407).
36. Laine CL, Newschaffer C, Zhang D, et al. Models of care in New York State Medicaid substance abuse clinics: range of services and linkages to medical care. J Subst Abuse 2000;12:271-285.
37. Samet JH, Friedmann P, Saitz R. Benefits of linking primary medical care and substance abuse services: patient, provider, and societal perspectives. Arch Intern Med 2001;161:85-91.
38. Umbricht-Schneiter A, Ginn DH, Pabst KM, et al. Providing medical care to methadone clinic patients: referral vs on-site care. Am J Public Health 1994;84:207-210.
39. Turner BJ, Newschaffer CJ, Zhang D, et al. Antiretroviral use and pharmacy-based measurement of adherence in post-partum HIV infected women. Med Care 2000;38:911-925.
40. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-87.